Topographical immunohistochemical expression of bcl-2 protein in human liver lesions

Anticancer Research

Volumn 16, Issue 2, 1996, Pages 975-978

  Skopelitou, Antigone ^a   Hadjiyannakis, Michael ^b,d   Alexopoulou, Vana ^c   Krikoni, Olga ^a   Kamina, Sevasti ^a   Agnantis, Niki ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b IASO GENERAL HOSPITAL   (Greece)

^c General Hospital of Volos   (Greece)

^d NONE   (Greece)

Author keywords

bcl 2 protein; Cholangiocarcinoma; Hepatocellular carcinoma; Immunohistochemistry; Liver

Indexed keywords

PROTEIN BCL 2;

ADENOCARCINOMA; ARTICLE; BILE DUCT; BILE DUCT CARCINOMA; CELL SURVIVAL; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; EPITHELIUM; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPEROXIDASE STAINING; LIVER CELL; LIVER CELL CARCINOMA; LIVER DISEASE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION;

ADENOCARCINOMA; BREAST NEOPLASMS; CARCINOMA, HEPATOCELLULAR; CHOLANGIOCARCINOMA; COLONIC NEOPLASMS; HUMANS; LIVER; LIVER DISEASES; LIVER NEOPLASMS; NEOPLASM PROTEINS; PRECANCEROUS CONDITIONS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 0029942365     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Bishop JM: The molecular genetics of cancer. Science 235: 305-311, 1987.
2. Bishop JM: Cellular oncogenes and retroviruses. Ann Rev Biochem 52: 301-354, 1983.
3. Fausto N, Shank PR: Oncogene expression in liver regeneration and hepatocarcinogenesis. Hepatology 3: 1016-1023, 1983.
4. Spandidos DA: A unified theory for the development of cancer. Biosci Rep 6:691-708, 1986.
5. Cleary ML, Sklar J: Nucleotide sequence of at (14;18) chromosomal breakpoint in follicular lymphomas and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18. Proc Natl Acad Sci USA 82: 7439-7443, 1985.
6. Yunis JJ, Oken MM, Kaplan ME, Ensrud KM, Howe RR, Theologides A: Distinctive chromosomal abnormalities in histologic subtypes of non-Hodgkin's lymphomas. N Engl J Med 307: 1231-1236, 1982.
7. Hockenbery DM, Zutter M, Hickey W, Nahm M, Korsmeyer SJ: bcl-2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA 88: 6961-6965, 1991.
8. Korsmeyer SJ: bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 80: 879-886, 1992.
9. Tsujimoto Y, Croce CM: Analysis of the structure, transcripts and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci 83: 5214-5218, 1986.
10. Tsujimoto Y, Gorham J, Cossman J, Jaffe E, Croce CM. Characterization of the protein product of bcl-2, the gene involved in human follicular lymphoma. Oncogene 2: 3-7, 1987.
11. Pezzella F, Ralfkiaer E, Gatter K, Mason DY. The incidence of the 14;18 translocation in European cases of follicular lymphoma. Br J Haematol 76: 58-64, 1990b.
12. Colombel M, Symmans F, Gil S, O'Toole KM, Chopin D, Benson M, Olsson CA, Korsmeyer S, Buttyan R: Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancer. Am J Pathol 143: 390-400, 1993.
13. Segal NH, Cohen RJ, Haffejee Z, Savage N bcl-2 proto-oncogene expression in prostate cancer and its relationship to the prostatic neuroendocrine cell. Arch Pathol Lab Med 118: 616-618, 1994.
14. Lu QL, Elia E, Lucas S, Thomas JA: bcl-2 proto-oncogene expression in Epstein-Barr virus associated nasopharyngeal carcinoma. Int J Cancer 53: 29-35, 1993.
15. Pezzella F, Turley H, Kuzu I et al: bcl-2 protein in non-small-cell lung carcinoma. Immunohistochemical evidence for abnormal expression and correlation with survival. New Engl J Med 329: 690-694, 1993.
16. Doglioni C, Dei Tos B, Laurino L, Chiarelli C, Barbareschi M, Viale G: The prevalence of bcl-2 immunoreactivity in breast carcinomas and its clinicopathological correlates, with particular reference to oestrogen receptor status. Virchows Arch 424: 47-51, 1994.
17. Zutter M, Hockenbery D, Silverman GA, Korsmeyer SJ: Immunolocalization of the bcl-2 protein within hematopoietic neoplasms. Blood 78: 1062-1068, 1991.
18. LeBrun DP, Warnke RA, Cleary ML: Expression of bcl-2 in fetal tissues suggests a role in morphogenesis. Am J Pathol 142: 743-753, 1993.
19. Terada T, Shimizu K, Izumi R, et al: P53 expression in formalin-fixed, paraffin-embedded archival specimens of intrahepatic cholangiocarcinoma: retrieval of p53 antigenicity by microwave oven heating of tissue sections. Modern Pathology 7: 249-252, 1994.
20. Pezzela F, Gatter K: What is the value of bcl-2 protein detection for histopathologists? Histopathology 26: 89-93, 1995.
21. Chen-Levy Z, Nourse J, Cleary M: The bcl-2 candidate protooncogene product is a 24-kilodalton integral membrane protein highly expressed in lymphoid cell lines and lymphomas carrying the t (14;18) translocation. Mol Cell Biol 9: 701-710, 1989.
22. Charlotte F, L'Hermine A, Martin N, Geleyn Y, Nollet M, Gaulard P, Zafrani ES: Immunohistochemical detection of bcl-2 protein in normal and pathological human liver. Am J Pathol 144: 460-465, 1994.
23. Farber E: Similarities in the sequence of early histological changes induced in the liver of the rat by ethionine, 2-acetylaminofluorene, and 3′-methyl-4-dimethylaminoazobenzene. Cancer Res 16: 142-148, 1956.
24. Evarts RP, Nagy P, Marsden E, Thogeirsson SS: A precursor-product relationship exists between oval cells and hepatocytes in rat liver. Carcinogenesis 8: 1737-1740, 1987.
25. Lemire JM, Shiojiri N, Fausto N: Oval cell proliferation and the origin of small hepatocytes in liver injury induced by D-galactosamine. Am J Pathol 139: 535-552, 1991.